PDCD1 and non-small cell lung carcinoma: These results indicated that CK2 inhibitors can effectively improve the exhaustion of CD8+ T cells, enhance the function of CD8+ T cells, and significantly enhance the efficacy of anti‐PD‐1 therapy in NSCLC.